Evaxion Biotech (EVAX) Tops Q1 EPS by 7c

Evaxion Biotech (NASDAQ: EVAX) reported Q1 EPS of ($0.23), $0.07 better than the analyst estimate of ($0.30).

Lars Wegner, CEO of Evaxion, said: “Evaxion made strong progress in Q1 2021, successfully concluding our U.S. IPO and continuing to advance our clinical programs. Our two lead product candidates, EVX-01 and EVX-02, are on track for results from Phase 1/2a trials late in Q2 and we continue to develop our RAVEN AI platform for vaccine design and development for viral infections. We believe that our cash reserves of $27 million provide a solid financial foundation and will facilitate the continued development of our four lead programs.”

For earnings history and earnings-related data on Evaxion Biotech (EVAX) click here.

You May Also Be Interested In

• Sinda raises $331M in IPO, reports Q2 net loss of $16.6M
• StablecoinX reports Q2 2026 results with $34.2M net loss
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c